A Multicenter, Open-label, Phase 1/1b, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SI-B037 in Solid Tumors
The objective of the study is to evaluate the safety and tolerability of SI-B037 in participants with locally advanced or metastatic solid tumors.
Trial Details
- NCT ID
- NCT07940881
- Phase
- PHASE1
- Sponsor
- SystImmune Inc.
- Status
- RECRUITING
- Cancer Type
- Melanoma
- Interventions
- Locations (sample)
- Houston, Texas, United States|29.76328,-95.36327
Key Eligibility Criteria
- Signed the informed consent form voluntarily and agreed to follow the trial requirements.
- Male or Female Age ≥18 years.
- Has a life expectancy of ≥3 months.
- Subjects with documented locally advanced or metastatic solid tumor(s) not amenable to curative surgery or radiation and have received at least 1 l…
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Melanoma Trials on Trialify →